Get started
Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Inc.Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

VNDA chart


Full chart

VNDA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪281.63 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.28 USD
Net income (FY)
‪2.51 M‬ USD
Revenue (FY)
‪192.64 M‬ USD
Shares float
‪55.22 M‬
Beta (1Y)
0.41

Employees


Employees (FY)
203
Change (1Y)
−87 −30.00%
Revenue / Employee (1Y)
‪948.97 K‬ USD
Net income / Employee (1Y)
‪12.36 K‬ USD

About Vanda Pharmaceuticals Inc.


Sector
Health Technology
CEO
Mihael Hristos Polymeropoulos
Headquarters
Washington
Website
vandapharma.com
Founded
2002
FIGI
BBG000HT5MG6
Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VNDA news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of VNDA is 4.83 USD — it has increased by 3.21% in the past 24 hours. Watch Vanda Pharmaceuticals Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Vanda Pharmaceuticals Inc. stocks are traded under the ticker VNDA.
VNDA stock has risen by 4.77% compared to the previous week, the month change is a −2.03% fall, over the last year Vanda Pharmaceuticals Inc. has showed a 24.81% increase.
We've gathered analysts' opinions on Vanda Pharmaceuticals Inc. future price: according to them, VNDA price has a max estimate of 18.00 USD and a min estimate of 5.50 USD. Watch VNDA chart and read a more detailed Vanda Pharmaceuticals Inc. stock forecast: see what analysts think of Vanda Pharmaceuticals Inc. and suggest that you do with its stocks.
VNDA reached its all-time high on Dec 3, 2018 with the price of 33.44 USD, and its all-time low was 0.45 USD and was reached on Dec 23, 2008. View more price dynamics on VNDA chart.
See other stocks reaching their highest and lowest prices.
VNDA stock is 3.87% volatile and has beta coefficient of 0.41. Track Vanda Pharmaceuticals Inc. stock price on the chart and check out the list of the most volatile stocks — is Vanda Pharmaceuticals Inc. there?
Today Vanda Pharmaceuticals Inc. has the market capitalization of ‪281.63 M‬, it has decreased by −1.06% over the last week.
Yes, you can track Vanda Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Vanda Pharmaceuticals Inc. is going to release the next earnings report on Feb 5, 2025. Keep track of upcoming events with our Earnings Calendar.
VNDA earnings for the last quarter are −0.09 USD per share, whereas the estimation was −0.16 USD resulting in a 42.55% surprise. The estimated earnings for the next quarter are −0.11 USD per share. See more details about Vanda Pharmaceuticals Inc. earnings.
Vanda Pharmaceuticals Inc. revenue for the last quarter amounts to ‪47.65 M‬ USD, despite the estimated figure of ‪49.17 M‬ USD. In the next quarter, revenue is expected to reach ‪52.25 M‬ USD.
VNDA net income for the last quarter is ‪−5.32 M‬ USD, while the quarter before that showed ‪−4.52 M‬ USD of net income which accounts for −17.84% change. Track more Vanda Pharmaceuticals Inc. financial stats to get the full picture.
No, VNDA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 203.00 employees. See our rating of the largest employees — is Vanda Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Vanda Pharmaceuticals Inc. EBITDA is ‪−30.16 M‬ USD, and current EBITDA margin is −5.68%. See more stats in Vanda Pharmaceuticals Inc. financial statements.
Like other stocks, VNDA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Vanda Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Vanda Pharmaceuticals Inc. technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Vanda Pharmaceuticals Inc. stock shows the sell signal. See more of Vanda Pharmaceuticals Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.